Medicofarma Biotech SA (WSE:MDB)
Poland
· Delayed Price · Currency is PLN 0.486
-0.012 (-2.41%)
At close: Apr 27, 2026
Medicofarma Biotech Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.12 | 1.22 | 0.75 | 4.25 | 3.34 | Upgrade
|
| Revenue Growth (YoY) | -90.21% | 63.14% | -82.34% | 27.45% | -8.59% | Upgrade
|
| Cost of Revenue | 1.22 | 1.48 | 0.96 | 3.73 | 2.35 | Upgrade
|
| Gross Profit | -1.1 | -0.26 | -0.21 | 0.53 | 0.99 | Upgrade
|
| Selling, General & Admin | 0.14 | 0.24 | 0.32 | 0.35 | 0.31 | Upgrade
|
| Other Operating Expenses | -0.94 | 0.03 | 0.12 | 0.01 | 0.01 | Upgrade
|
| Operating Expenses | 0.6 | 1.82 | 2.42 | 2.1 | 1.27 | Upgrade
|
| Operating Income | -1.7 | -2.07 | -2.63 | -1.58 | -0.28 | Upgrade
|
| Interest Expense | -0.62 | -0.24 | -0.17 | -0.01 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -2.33 | -2.32 | -2.81 | -1.59 | -0.33 | Upgrade
|
| Impairment of Goodwill | 0.1 | - | 0.1 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.04 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.07 | Upgrade
|
| Asset Writedown | - | - | -0.94 | - | - | Upgrade
|
| Pretax Income | -2.23 | -2.32 | -3.65 | -1.59 | -0.22 | Upgrade
|
| Income Tax Expense | - | -0.02 | -0.21 | - | - | Upgrade
|
| Net Income | -2.23 | -2.3 | -3.44 | -1.59 | -0.22 | Upgrade
|
| Net Income to Common | -2.23 | -2.3 | -3.44 | -1.59 | -0.22 | Upgrade
|
| Shares Outstanding (Basic) | 68 | 68 | 68 | 68 | 68 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 68 | 68 | 68 | 68 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | 901.99% | Upgrade
|
| EPS (Basic) | -0.03 | -0.03 | -0.05 | -0.02 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.03 | -0.05 | -0.02 | -0.00 | Upgrade
|
| Free Cash Flow | -0.98 | -1.02 | -1.1 | -0.25 | -0.48 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.00 | -0.01 | Upgrade
|
| Gross Margin | - | -21.07% | -27.80% | 12.35% | 29.64% | Upgrade
|
| Operating Margin | -1418.73% | -169.34% | -350.57% | -37.07% | -8.53% | Upgrade
|
| Profit Margin | -1860.32% | -187.82% | -458.07% | -37.38% | -6.45% | Upgrade
|
| Free Cash Flow Margin | -820.32% | -83.23% | -146.38% | -5.83% | -14.48% | Upgrade
|
| EBITDA | -0.21 | -0.53 | -0.55 | 0.17 | 0.67 | Upgrade
|
| EBITDA Margin | -173.66% | -42.94% | -72.92% | 4.04% | 19.97% | Upgrade
|
| D&A For EBITDA | 1.49 | 1.55 | 2.08 | 1.75 | 0.95 | Upgrade
|
| EBIT | -1.7 | -2.07 | -2.63 | -1.58 | -0.28 | Upgrade
|
| EBIT Margin | - | -169.34% | - | -37.07% | -8.53% | Upgrade
|
| Revenue as Reported | 0.12 | 1.22 | 0.75 | 4.25 | 3.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.